Related Experiment Video
Updated: Jun 25, 2025

03:25
Simple Continuous Glucose Monitoring in Freely Moving Mice
Published on: February 24, 2023
5.4K
GLSTM: On Using LSTM for Glucose Level Prediction
Muhammad Kashif1, Sergio Flesca1, Pierangelo Veltri1
1DIMES University of Calabria, Italy.
Studies in Health Technology and Informatics
|May 24, 2024
Summary
This study uses a Long Short-Term Memory (LSTM) model to forecast glucose levels in individuals with prediabetes. The goal is to improve glycemic health management and prevent progression to type 2 diabetes.
Area of Science:
- Endocrinology and Metabolic Diseases
- Biomedical Data Science
- Artificial Intelligence in Healthcare
Background:
- Prediabetes affects one in three individuals, with a 10% annual risk of progressing to type 2 diabetes without intervention.
- Effective glycemic health management is crucial for preventing type 2 diabetes progression.
- Limited noninvasive methods exist for tracking glycemic status, hindering prediabetes self-management.
Purpose of the Study:
- To develop and evaluate a personalized Long Short-Term Memory (LSTM) model for forecasting glucose levels in prediabetes.
- To provide a tool for improved self-management of prediabetes and glycemic health.
Main Methods:
- Utilized personalized prediabetes data including continuous interstitial glucose levels, heart rate, and weekly dietary records.
- Employed a Long Short-Term Memory (LSTM) neural network model for glucose level forecasting.
- Assessed model performance using Root Mean Square Error (RMSE), Mean Squared Error (MSE), Mean Absolute Error (MAE), and R2 coefficient.
Main Results:
- The LSTM model demonstrated efficacy in forecasting glucose levels using personalized prediabetes data.
- Quantitative evaluation metrics (RMSE, MSE, MAE, R2) were used to assess the model's predictive accuracy.
Conclusions:
- The proposed LSTM model shows promise as a noninvasive tool for monitoring glycemic status in prediabetes.
- Personalized glucose forecasting can support self-management strategies for individuals with prediabetes, potentially deterring progression to type 2 diabetes.
Related Concept Videos
Glucagon-like Receptor Agonists
318
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
318
Hormones Regulating Blood Glucose
3.2K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.2K
Hypoglycemia and Glucagon
256
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
256
Glucose Homeostasis: Regulation of Blood Glucose
1.6K
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
1.6K
Glucose Transporters
22.7K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.7K
Glucose Absorption Into the Small Intestine
31.6K
Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and...
31.6K

